Thursday, November 12, 2026

Dollar Plunges to Three-Year Low as Euro Surges 14%, Pound Hovers Near $1.30 Breakdown

The US Dollar fell to its lowest level since 2022, driving the Euro up 14% and the British Pound 7% higher in 2025. The currency realignment reshapes global investment flows as central banks diverge on monetary policy, with UK gilt yields hitting 27-year highs at 5.21%.

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
Dollar Plunges to Three-Year Low as Euro Surges 14%, Pound Hovers Near $1.30 Breakdown
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The US Dollar hit its weakest level since 2022, triggering a global currency realignment that lifted the Euro 14% and the British Pound 7% this year. The shift reverses two years of dollar dominance and reshapes cross-border investment flows.

GBP traded at $1.3086 but faces pressure from deteriorating UK fundamentals. Jordan Rochester at Mizuho Bank forecasts a drop below $1.30 despite recent gains. The pound fell 0.5% against the dollar and 0.4% versus the euro to €1.13, its lowest since April 2023.

UK 30-year gilt yields climbed to 5.21%, the highest since 1998, as inflation concerns weigh on sterling. Chancellor Rachel Reeves' November 26 budget is expected to announce tax increases. "GBP under pressure," said Simon Phillips at No1 Currency.

European markets rallied on dollar weakness. The Stoxx 600 hit a record 583.4 points as the weaker dollar boosts eurozone exporters. London's FTSE 100 closed at 9,911, near its all-time high. The Swiss Franc gained alongside the euro, signaling persistent safe-haven demand despite the risk-on rotation.

Gold traded above $4,100 per ounce, reinforcing flight-to-quality flows. The currency moves create the largest FX shifts since the 2022 energy crisis, driven by diverging monetary policy expectations. Markets anticipate US rate cuts while European central banks maintain tighter policy.

For global investors, the dollar's decline benefits international equity holdings for US-based funds while creating headwinds for emerging market dollar-denominated debt. European equity exposure gains currency tailwinds.

GBP/USD offers near-term trading opportunities around the $1.30 technical level. A breakdown could trigger stop-loss selling toward $1.28. EUR/USD momentum remains strong but faces resistance at 2022 highs. Watch UK economic data for early signals of pound vulnerability and Swiss Franc flows as a gauge of underlying risk appetite.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com